Drugs / K-1728
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07861932 | Oct 2026 → Sep 2028 expected | breast neoplasm | KymaThera, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | K-1728 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07861932 ↗ |
| Route | Oral | “K-1728 will be administered orally once daily in 28-day cycles” NCT07861932 ↗ |